Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer

NCT04123704 is registered in ClinicalTrials.gov with Xiang Zhang as lead sponsor.

NCT NCT04123704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04123704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer
Lead sponsor
Xiang Zhang
Phase
Phase 2
Overall status
Terminated
Start date
September 22, 2021
Completion date
January 22, 2023
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, breast cancer stage iv, breast neoplasms, triple negative breast cancer